Ann: Trading Update, page-122

I think the update is more troublesome then investors realise. I personally would be very wary getting in. More competition and new treatments coming on stream could render SRX's late stage therapy not very appealing. That's one of the issues which could result in much lower growth sales and doses then anyone could imagine. Patients at the end will choose a treatment that gives them the best chance of a longer life. Plus the risks also come from better options and treatments coming on line at early stage which could potentially lower the number of patients down the line.